Esomeprazole and Radiation Induced Esophagitis

Conditions

• Locally Advanced Lung Carcinoma
• Radiation Esophagitis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Esomeprazole 40 mg — DRUG
  Enrolled patients will receive 40 mg of esomeprazole (two pills of 20 mg strength of esomeprazole) once daily before breakfast for the entire duration of TRT (including the weekends and any interim gap period) and for two weeks after completion of thoracic radiation therapy.

Study Details

Thoracic radiation therapy combined with chemotherapy (with or without immunotherapy) is the cornerstone of management in patients with locally advanced non-small cell lung cancer (NSCLC).

Key Dates

Start date

Mar 1, 2024

Status verified

Apr 2025

Primary completion

Dec 30, 2027

Completion

Jun 30, 2028

Study Design

Enrollment

48 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Esomeprazole 40 mg daily with thoracic radiation therapy and concomitant chemotherapy
  Enrolled patients will receive 40 mg of esomeprazole (two pills of 20 mg strength of esomeprazole) once daily before breakfast for the entire duration of TRT (including the weekends and any interim gap period) and for two weeks after completion of thoracic radiation therapy (TRT). TRT will be delivered as per the discretion of the treating physicians.

Primary Outcome Measure

Grade 2 or higher radiation induced esophagitis [ Time Frame: At 2 weeks after completion of thoracic radiation therapy and at 3 months since start of radiation therapy ]

Central Contacts

• Soumyajit Roy, MD, MSc.(c)
  312-942-5655
  [email protected]
• Gaurav Marwaha, MD
  312-942-5751
  [email protected]

Locations (1)

Find similar trials in Chicago, IL

Related Studies

• Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
  Recruiting · Jun Zhang, MD, PhD · Kansas City, Kansas
• Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
  Recruiting · Mayo Clinic · Rochester, Minnesota